((lp0
VisWord
p1
aVcase
p2
aVstops
p3
aVstem
p4
accopy_reg
_reconstructor
p5
(cnltk.probability
FreqDist
p6
c__builtin__
dict
p7
(dp8
S'concept'
p9
I1
sS'disease progression stag'
p10
I1
sS'consider'
p11
I5
sS'endpoint of'
p12
I1
sS'final visit'
p13
I1
sS'random'
p14
I2
sS'unique model'
p15
I1
sS'code'
p16
I1
sS'dbp'
p17
I3
sS'nifedipine-git'
p18
I1
sS'titration studi'
p19
I1
sS'ground'
p20
I1
sS'niacin'
p21
I1
sS'articl'
p22
I1
sS'double-blind studi'
p23
I1
sS'parametr'
p24
I1
sS'program'
p25
I2
sS'vasodilatori'
p26
I1
sS'relative comparison of th'
p27
I1
sS'treatment effect of'
p28
I2
sS'relative comparison of'
p29
I1
sS'clinical practic'
p30
I1
sS'practical quest'
p31
I1
sS'exercise capac'
p32
I1
sS'parallel groups tri'
p33
I1
sS'publishing industri'
p34
I1
sS'commercial computer softwar'
p35
I1
sS'of niacin'
p36
I2
sS'six-month'
p37
I1
sS'subfract'
p38
I1
sS'respond'
p39
I2
sS'prevent'
p40
I1
sS'titration study of omapatrilat'
p41
I1
sS'semi-observational studi'
p42
I1
sS'investig'
p43
I4
sS'imput'
p44
I2
sS'randomized subject'
p45
I2
sS'lipoprotein subfract'
p46
I1
sS'pmi'
p47
I5
sS'subject'
p48
I6
sS'statu'
p49
I3
sS'compar'
p50
I1
sS'ich-e9 guidelin'
p51
I1
sS'review'
p52
I2
sS'particip'
p53
I1
sS'clinical statu'
p54
I3
sS'abbrevi'
p55
I1
sS'on harmon'
p56
I1
sS'new'
p57
I1
sS'approach'
p58
I1
sS'locf last-observation-carried-forward'
p59
I1
sS'conventional last-observation-carried-forward'
p60
I1
sS'assumpt'
p61
I1
sS'kaplan-mei'
p62
I1
sS'numer'
p63
I1
sS'ciltexetil'
p64
I1
sS'locf for'
p65
I1
sS'semi-observational study imbed'
p66
I1
sS'cardiovascular death'
p67
I2
sS'study imbed'
p68
I1
sS'ventricular mass'
p69
I1
sS'drug'
p70
I1
sS'omapatrilat'
p71
I1
sS'trial'
p72
I14
sS'survey'
p73
I1
sS'new york heart association class'
p74
I1
sS'bp'
p75
I11
sS'studi'
p76
I17
sS'literatur'
p77
I1
sS'mirror image of th'
p78
I1
sS'cancer'
p79
I1
sS'guidelin'
p80
I1
sS'hydrochlorothiazid'
p81
I2
sS'study treat'
p82
I1
sS'subgroup pati'
p83
I1
sS'outcome-correlated baselin'
p84
I1
sS'study sampl'
p85
I1
sS'explanatory tri'
p86
I1
sS'pimobendan'
p87
I1
sS'association class iv'
p88
I1
sS'visit'
p89
I3
sS'systolic blood'
p90
I1
sS'imbed'
p91
I1
sS'mark'
p92
I1
sS'treat'
p93
I1
sS'pi'
p94
I1
sS'life'
p95
I1
sS'non-parametr'
p96
I1
sS'dropout'
p97
I1
sS'flaw'
p98
I1
sS'diastolic blood'
p99
I2
sS'protocol viol'
p100
I1
sS'lovastatin'
p101
I1
sS'verapamil-sr'
p102
I1
sS'examin'
p103
I1
sS'treatment effect of pimobendan'
p104
I1
sS'primary pre-specified analysis of exercis'
p105
I1
sS'parallel-design studi'
p106
I1
sS'endpoint'
p107
I7
sS'journal articl'
p108
I1
sS'histori'
p109
I1
sS'randomized tri'
p110
I1
sS'post-hoc'
p111
I1
sS'outcom'
p112
I1
sS'mirror image of'
p113
I1
sS'clinical studi'
p114
I1
sS'observ'
p115
I4
sS'practition'
p116
I3
sS'locf'
p117
I12
sS'medical publish'
p118
I1
sS'medical visit'
p119
I1
sS'registr'
p120
I1
sS'diabetes tri'
p121
I1
sS'calcul'
p122
I2
sS'iv'
p123
I1
sS'topic'
p124
I1
sS'terminal diseas'
p125
I1
sS'international confer'
p126
I1
sS'atorvastatin'
p127
I1
sS'ie'
p128
I1
sS'statistical literatur'
p129
I1
sS'endpoint of cardiovascular death'
p130
I1
sS'medic'
p131
I1
sS'negative studi'
p132
I1
sS'study therapi'
p133
I2
sS'research top'
p134
I1
sS'misconcept'
p135
I1
sS'popular practic'
p136
I1
sS'hypertens'
p137
I1
sS'time-point'
p138
I4
sS'post-therapy observ'
p139
I1
sS'multiple imput'
p140
I1
sS'mar'
p141
I1
sS'international conference on'
p142
I1
sS'mortal'
p143
I1
sS'tool'
p144
I1
sS'covari'
p145
I1
sS'primary endpoint'
p146
I1
sS'new york'
p147
I1
sS'harmon'
p148
I2
sS'attempt'
p149
I1
sS'practic'
p150
I2
sS'loss-to-follow-up'
p151
I1
sS'restrictive model'
p152
I1
sS'clinical trial practition'
p153
I2
sS'question mark'
p154
I1
sS'trial monitor'
p155
I1
sS'analytical studi'
p156
I1
sS'withdraw'
p157
I14
sS'abbreviations bp'
p158
I1
sS'model'
p159
I7
sS'partial imput'
p160
I1
sS'subgroup'
p161
I3
sS'protocol'
p162
I1
sS'multicent'
p163
I3
sS'intent to'
p164
I1
sS'dropout categori'
p165
I1
sS'collabor'
p166
I1
sS'candesartan ciltexetil'
p167
I1
sS'itt'
p168
I8
sS'death'
p169
I4
sS'monitor'
p170
I1
sS'pragmatic tri'
p171
I1
sS'treatment'
p172
I19
sS'exercis'
p173
I11
sS'within-subject vari'
p174
I1
sS'survey research'
p175
I1
sS'potential bia'
p176
I1
sS'atherogenic dyslipidemia'
p177
I1
sS'therapi'
p178
I2
sS'bia'
p179
I1
sS'introduct'
p180
I1
sS'titration study of'
p181
I1
sS'proper multiple imput'
p182
I1
sS'medical journal articl'
p183
I1
sS'study of omapatrilat'
p184
I1
sS'chronic heart'
p185
I1
sS'2i'
p186
I2
sS'treatment cod'
p187
I1
sS'study conclus'
p188
I1
sS'dyslipidemia'
p189
I1
sS'practical usag'
p190
I1
sS'intern'
p191
I1
sS'sampl'
p192
I1
sS'mirror'
p193
I1
sS'hemodynam'
p194
I1
sS'event'
p195
I1
sS'baselin'
p196
I1
sS'variabl'
p197
I3
sS'ich'
p198
I2
sS'york heart association class iv'
p199
I1
sS'research'
p200
I2
sS'categori'
p201
I1
sS'four-week'
p202
I1
sS'post-randomization stratif'
p203
I1
sS'patient'
p204
I3
sS'all-cause mort'
p205
I1
sS'prevention studi'
p206
I1
sS'usag'
p207
I1
sS'regression model'
p208
I3
sS'treatment effect of niacin'
p209
I1
sS'last-observation-carried-forward'
p210
I2
sS'stage'
p211
I1
sS'trial practition'
p212
I2
sS'review attempt'
p213
I1
sS'popular approach'
p214
I1
sS'cardiovascular ev'
p215
I1
sS'new york heart'
p216
I1
sS'to treat'
p217
I1
sS'industri'
p218
I1
sS'blood'
p219
I1
sS'softwar'
p220
I2
sS'misl'
p221
I1
sS'cancer histori'
p222
I1
sS'end-of-observ'
p223
I1
sS'rank'
p224
I1
sS'surviv'
p225
I3
sS'clinical tri'
p226
I8
sS'pre-specified model'
p227
I1
sS'open-label'
p228
I1
sS'question'
p229
I3
sS'capac'
p230
I1
sS'of omapatrilat'
p231
I1
sS'non-cardiovascular death'
p232
I1
sS'new york heart association class iv'
p233
I1
sS'termin'
p234
I1
sS'coronary vasodilatori'
p235
I1
sS'relative comparison of the treat'
p236
I1
sS'drug registr'
p237
I1
sS'hctz'
p238
I3
sS'essential hypertens'
p239
I1
sS'class iv'
p240
I1
sS'conclus'
p241
I1
sS'longitudinal studi'
p242
I1
sS'ground rul'
p243
I1
sS'enalapril'
p244
I1
sS'stratif'
p245
I1
sS'observational studi'
p246
I2
sS'primary response vari'
p247
I1
sS'medical journ'
p248
I1
sS'terminal disease progress'
p249
I1
sS'restrictive assumpt'
p250
I1
sS'statistical tool'
p251
I1
sS'progression stag'
p252
I1
sS'statistical concept'
p253
I1
sS'decreas'
p254
I1
sS'complet'
p255
I4
sS'medical publishing industri'
p256
I1
sS'proport'
p257
I1
sS'incompar'
p258
I1
sS'mmhg decreas'
p259
I1
sS'advic'
p260
I1
sS'technical review'
p261
I1
sS'double-blind'
p262
I3
sS'violat'
p263
I1
sS'denomin'
p264
I3
sS'mass'
p265
I1
sS'baseline covari'
p266
I1
sS'conference on harmon'
p267
I1
sS'medical investig'
p268
I2
sS'distribut'
p269
I1
sS'intent to treat'
p270
I1
sS'intent'
p271
I1
sS'statistical model'
p272
I1
sS'visit time-point'
p273
I1
sS'primary pre-specified analysis of'
p274
I1
sS'randomized pati'
p275
I2
sS'heart association class iv'
p276
I1
sS'mcar'
p277
I9
sS'rule'
p278
I1
sS'of pimobendan'
p279
I2
sS'of cardiovascular death'
p280
I1
sS'international conference on harmon'
p281
I1
sS'terminal disease progression stag'
p282
I1
sS'study med'
p283
I1
sS'new york heart associ'
p284
I1
stp285
Rp286
(dp287
S'_N'
p288
I486
sS'_max_cache'
p289
NsS'_item_cache'
p290
NsS'_Nr_cache'
p291
Nsbtp292
.